Weber Capital Management LLC ADV Invests $1.27 Billion in Accuray Incorporated $ARAY

Posted by Brian Himes on Aug 24th, 2026

Weber Capital Management LLC ADV acquired a new stake in shares of Accuray Incorporated (NASDAQ:ARAY – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,932,706 shares of the medical equipment provider’s stock, valued at approximately $1,271,652,000. Accuray comprises about 1.1% of Weber Capital Management LLC ADV’s holdings, making the stock its 12th largest holding. Weber Capital Management LLC ADV owned 4.15% of Accuray at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new position in Accuray in the third quarter valued at approximately $35,000. Janney Montgomery Scott LLC acquired a new stake in shares of Accuray during the 4th quarter worth approximately $41,000. Oxford Asset Management LLP bought a new stake in shares of Accuray in the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC lifted its holdings in shares of Accuray by 604.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 35,177 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 30,182 shares during the last quarter. Finally, Williams & Novak LLC boosted its position in Accuray by 30.9% during the 2nd quarter. Williams & Novak LLC now owns 238,230 shares of the medical equipment provider’s stock valued at $61,000 after purchasing an additional 56,200 shares during the period. Institutional investors and hedge funds own 64.08% of the company’s stock.

Accuray Stock Performance

NASDAQ:ARAY opened at $0.28 on Monday. The stock has a market cap of $33.43 million, a price-to-earnings ratio of -0.70 and a beta of 1.39. The company has a debt-to-equity ratio of 3.21, a quick ratio of 0.66 and a current ratio of 1.42. Accuray Incorporated has a 1 year low of $0.22 and a 1 year high of $2.10. The business has a fifty day moving average of $0.28 and a 200-day moving average of $0.38.

Accuray (NASDAQ:ARAY – Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The medical equipment provider reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $100.92 million for the quarter, compared to analysts’ expectations of $105.30 million. Accuray had a negative net margin of 12.24% and a negative return on equity of 92.88%.

Analyst Ratings Changes

Several equities research analysts have weighed in on ARAY shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Accuray in a research report on Tuesday, August 4th. Jefferies Financial Group cut shares of Accuray from a “buy” rating to a “hold” rating in a report on Tuesday, May 12th. Finally, BTIG Research reiterated a “neutral” rating on shares of Accuray in a research report on Wednesday, July 8th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $2.00.

Get Our Latest Report on ARAY

Accuray Company Profile

(Free Report)

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.